Evidence map›Paper›PMID 30934592›Full record

ArticleVeterinary sciences2019

Immunostaining for p53 and p16

John S Munday, Harsha Ariyarathna, Danielle Aberdein, Neroli A Thomson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Veterinary sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Low-Invasive Biomarkers of Canine Mammary Tumours.Veterinary medicine and science · 2025
    Review
  2. Canine Mammary Cancer: State of the Art and Future Perspectives.Animals : an open access journal from MDPI · 2023
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

John S MundayPathobiology, School of Veterinary Science, Massey University, Palmerston North 4442, New Zealand. j.munday@massey.ac.nz.ORCID 0000-0002-4769-5247
Harsha AriyarathnaPathobiology, School of Veterinary Science, Massey University, Palmerston North 4442, New Zealand. h.ariyarathna@massey.ac.nz.
Danielle AberdeinPathobiology, School of Veterinary Science, Massey University, Palmerston North 4442, New Zealand. d.aberdein@massey.ac.nz.
Neroli A ThomsonPathobiology, School of Veterinary Science, Massey University, Palmerston North 4442, New Zealand. n.thomson1@massey.ac.nz.
Massey University · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mammary gland tumors (MGTs) are common in dogs and show a variable clinical behavior that is difficult to predict. Currently, few immunohistochemical markers have been established to predict the prognosis of a canine MGT. However, p53 immunostaining has been variably reported to be prognostic for canine MGTs. Additionally, while p16

Indexed as

canine mammary gland neoplasiaimmunostainingp16p53prognosis

Identifiers

PMID30934592
PMCPMC6466101
OpenAlexW2924722371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.